Short answer · Medically reviewed summary · Last updated: 2026-05-08
Eosinophilic Fasciitis, also known as Shulman’s syndrome, was first identified in 1974 by Dr. Lawrence Shulman, who described a condition characterized by painful skin induration and peripheral eosinophilia.
What is the history of Eosinophilic Fasciitis?
History of Eosinophilic Fasciitis: when and how it was discovered, and the milestones in research since, medically reviewed.
Eosinophilic Fasciitis, also known as Shulman’s syndrome, was first identified in 1974 by Dr. Lawrence Shulman, who described a condition characterized by painful skin induration and peripheral eosinophilia. While initially confused with systemic sclerosis, medical understanding has evolved to recognize Eosinophilic Fasciitis as a distinct inflammatory disorder of the fascia that typically responds well to corticosteroid therapy.
When and how was Eosinophilic Fasciitis first described?
In 1974, Dr. Lawrence Shulman published a landmark report describing two patients with diffuse fasciitis and eosinophilia. This discovery provided a critical clinical distinction for Eosinophilic Fasciitis, allowing physicians to differentiate it from scleroderma, which was a common historical misdiagnosis due to the shared symptom of skin hardening.
How has the understanding of Eosinophilic Fasciitis evolved?
Early researchers viewed Eosinophilic Fasciitis primarily as a skin-deep condition. However, modern clinical literature has refined our understanding, acknowledging that it involves deep connective tissue inflammation. Advancements in diagnostic imaging, particularly MRI, have revolutionized how we visualize the fascial thickening characteristic of Eosinophilic Fasciitis, moving away from reliance on invasive full-thickness biopsies.
What are the major milestones in treatment and research?
The management of Eosinophilic Fasciitis has seen significant progress since its initial description. Key milestones include:
- Corticosteroids: The established first-line treatment that often leads to dramatic improvement in patients.
- Steroid-sparing agents: The introduction of methotrexate and other immunosuppressants for patients who are refractory to standard steroid protocols.
- Imaging technology: The use of MRI and PET scans to monitor disease activity and therapeutic response.
How has patient advocacy changed the landscape?
Historically, patients with rare conditions often felt isolated. Today, the Eosinophilic Fasciitis community has grown through platforms like DiseaseMaps.org, where 14 community members currently share their lived experiences. This digital connectivity allows patients to compare symptom patterns and treatment journeys, which is essential for a disease with such a low prevalence.
Next steps
- Consult a rheumatologist or dermatologist specializing in connective tissue diseases for a comprehensive evaluation.
- Connect with the 14 members of the DiseaseMaps.org Eosinophilic Fasciitis community to share insights.
- Discuss current clinical trials regarding immunosuppressive therapies with your medical team.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Eosinophilic Fasciitis.
- Orphanet: Shulman syndrome (ORPHA:3297).
- OMIM (Online Mendelian Inheritance in Man): Eosinophilic Fasciitis entry.
- PubMed: Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians. 1974.
